ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP76-21 Commercial and MHCP Pharmacy Benefit Exclusion for Uptravi®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 13, 2021
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1521 - 1530 လၢ 3613 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP77-21 Commercial Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective December 1, 2021
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP78-21 Commercial Pharmacy Benefit Update – New Drug-Related Quantity Limit (QL) Criteria: Stromectol® (ivermectin)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP79-21 New Availity Appeal Portal Available to Create, Submit and Inquire on Post Service Claim Appeals
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 13, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P53-21 Update for New-to-Market Medical Drug: aducanumab (Aduhelm)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2021 October Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P58-21 2022 Renewal Changes Summary for Institutional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Erectile Dysfunction - Phosphodiesterase Type 5 Inhibitors, Topical Prostaglandin - Commercial
Quantity Limit
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Enspryng (satralizumab-mwge) - Medicaid
Prior Authorization, Quantity Limit
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Enspryng (satralizumab-mwge) - Commercial
Prior Authorization, Quantity Limit
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2025